Table 1 Baseline characteristics of patient cohorts

Age (median)

46.4 ± 10.2

46.1 ± 11.0

0.308

 Range

23.5-74.1

22.4 – 74.0

  < 40 years

48 (23.6)

28 (33.3)

  ≥ 40 years

155 (76.4)

56 (66.7)

Histology

0.654

 IDC^a

180 (88.7)

76 (90.5)

 Others

23 (11.3)

8 (9.5)

Stage

<0.001

 I

55 (27.1)

15 (17.9)

 IIA

94 (46.3)

18 (21.4)

 IIB

33 (16.3)

9 (11.9)

 IIIA

13 (6.4)

26 (31.0)

 IIIB

0 (0)

1 (1.2)

 IIIC

8 (3.9)

14 (16.7)

 Unknown

0 (0)

1 (1.2)

Nuclear grade

0.191

 1

2 (1.0)

0 (0)

 2

47 (23.2)

18 (21.4)

 3

145 (71.4)

57 (67.9)

 Unknown

9 (4.4)

9 (10.7)

Histologic grade

0.411

 1

3 (1.5)

1 (1.2)

 2

45 (22.2)

20 (23.8)

 3

144 (70.9)

54 (64.3)

 Unknown

11 (5.4)

9 (10.7)

RNA expression (log2 scale, median)

 EGFR

7.0 ± 1.1

7.6 ± 1.2

0.456

 ERBB2

9.0 ± 1.0

9.4 ± 1.6

0.439

 ERBB3

7.2 ± 1.0

7.7 ± 1.0

0.503

 ERBB4

1.3 ± 1.4

2.3 ± 2.2

0.302

 ESR1

4.4 ± 0.1

4.5 ± 2.0

0.425

Chemotherapy

NA

 Adjuvant

203 (100)

60 (71.4)

 Neoadjuvant

0 (0)

24 (28.6)

 Unknown

0 (0)

0 (0)

Regimen

NA

 CMF¹

86 (42.4)

10 (11.9)

 FAC²

58 (28.6)

16 (19.0)

 AC³

17 (8.4)

5 (6.0)

 AC –T(H)⁴

41 (20.2)

46 (54.8)

 Hormone

0 (0)

0 (0)

 Unknown

1 (0.5)

7 (8.3)

Adjuvant RTx⁵

0.161

 Yes

130 (64.0)

61 (72.6)

 No

73 (36.0)

23 (27.4)